<DOC>
	<DOCNO>NCT00022334</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's white blood cell mixed tumor protein may make body build immune response kill tumor cell . PURPOSE : Phase I/II trial study effectiveness vaccine therapy treat patient liver cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose alpha-fetoprotein peptide-pulsed autologous dendritic cell HLA-A*0201-positive patient hepatocellular carcinoma . - Determine safety toxicity regimen patient . - Determine immunological effect regimen patient . - Determine progression-free survival clinical response patient treat regimen . OUTLINE : This dose-escalation study . Patients receive alpha-fetoprotein peptide-pulsed autologous dendritic cell intradermally day 1 . Treatment repeat every 2 week total 3 dos absence unacceptable toxicity . Cohorts 3-12 patient receive escalate dos vaccine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 2 12 patient experience dose-limiting toxicity . Patients follow week 1 , 4 , 12 every 6 month thereafter . PROJECTED ACCRUAL : A total 12-18 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>HLAA*0201 positive adult age 18 . Have HCC serum AFP determination &gt; 30ng/ml . Both male female patient may enrol . Karnofsky Performance Status great equal 70 percent . No previous evidence class 3 great New York Heart Association cardiac insufficiency coronary artery disease . No previous evidence opportunistic infection . Adequate baseline hematological function assess follow laboratory value 30 day prior study entry : 1 . Hemoglobin &gt; 9.0g/dl 2 . Platelets &gt; 50000/mm3 3 . Absolute Neutrophil Count &gt; 1,000/mm3 ChildPugh Class A B chronic liver disease . Ability give inform consent . Any congenital acquire condition lead inability generate immune response , include concomitant immune suppressive therapy . Concomitant steroid therapy chemotherapy , treatment &lt; 30 day first vaccination . Females childbearing potential must negative serum betaHCG pregnancy test ( within Day 14 Day 0 ) . Acute infection : acute viral , bacterial , fungal infection , require specific therapy . Acute therapy must complete within 14 day prior study treatment . HIVinfected patient . Patients underlying condition would contraindicate therapy study treatment . Patients organ allograft . O2 sit &lt; 91 % room air ; dyspnea rest .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>localize resectable adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
</DOC>